Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Director departure
Quarterly results

INHIBITEX, INC. (INHX) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/09/2012 PRN Inhibitex, Inc. Shareholder Alert: The Briscoe Law Firm and Powers Taylor, LLP Investigate the Board of Inhibitex, Inc. Concerning the Sale of INHX to Bristol-Myers Squibb
06/01/2011 BW Inhibitex to Present at the Jefferies 2011 Global Healthcare Conference
05/09/2011 BW Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study
05/06/2011 BW Inhibitex Reports First Quarter 2011 Financial Results and Corporate Highlights
04/27/2011 BW Inhibitex to Host Conference Call to Report First Quarter Financial Results on May 6, 2011
04/26/2011 BW Inhibitex to Present at Two Upcoming Investor Conferences
04/12/2011 BW Inhibitex Announces Exercise of Underwriters' Overallotment Option and Closing of Underwritten Public Offering
04/07/2011 PRN Inhibitex Prices $47 Million Public Offering
04/06/2011 BW Inhibitex Announces Proposed Public Offering
03/31/2011 BW Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189
03/31/2011 BW Inhibitex Announces Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
03/11/2011 BW Inhibitex Reports Fourth Quarter and Calendar Year 2010 Financial Results and Corporate Highlights
03/10/2011 BW Inhibitex to Present at the ROTH 23rd Annual Growth Stock Conference
03/02/2011 BW Inhibitex to Present at the Cowen and Company 31st Annual Health Care Conference
02/28/2011 BW Inhibitex to Host Conference Call to Report Fourth Quarter and Year-End 2010 Financial Results on March 11, 2011
02/11/2011 BW Inhibitex Receives Fast Track Designation for INX-189 for the Treatment of Chronic Hepatitis C Infections
12/13/2010 BW Inhibitex to Present at the 2010 Deutsche Bank BioFEST Conference on Tuesday, December 14th
12/13/2010 BW Inhibitex Reports Promising Top-Line Results from Phase II Trial of FV-100 for the Treatment of Shingles
11/09/2010 BW Inhibitex Reports Third Quarter Financial Results and Corporate Highlights
11/03/2010 BW Inhibitex Awarded $489,000 in Grants under the Therapeutic Discovery Tax Credit Program
11/01/2010 BW Inhibitex Initiates Phase 1b Multiple Ascending Dose Trial of INX-189 in Patients with Chronic Hepatitis C
10/29/2010 BW Inhibitex to Present at Two Upcoming Investor Conferences
10/29/2010 BW Inhibitex to Host Conference Call to Report Third Quarter Financial Results on November 9, 2010
10/15/2010 BW Inhibitex Completes Enrollment in Phase II Clinical Trial of FV-100 in Shingles Patients
09/13/2010 BW Inhibitex to Present at Three Upcoming Conferences
08/10/2010 BW Inhibitex to Present at the Canaccord Genuity 30th Annual Growth Conference on Thursday, August 12th
08/10/2010 BW Inhibitex Reports Second Quarter Financial Results and Corporate Highlights
07/29/2010 BW Inhibitex to Host Conference Call to Report Second Quarter Financial Results on August 10, 2010
07/22/2010 BW Inhibitex Reports Independent Data Safety Monitoring Board Recommends Continuation of Phase II Clinical Trial of FV-100
06/28/2010 BW Inhibitex Added to Russell 3000® Index
05/13/2010 BW Inhibitex Reports First Quarter Financial Results and Corporate Highlights
04/30/2010 BW Inhibitex to Host Conference Call to Report First Quarter Financial Results on May 13, 2010
03/23/2010 BW Inhibitex Reports Fourth Quarter and Calendar Year 2009 Financial Results and Corporate Highlights

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy